Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy
Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Home/Stocks/CBIO/Catalyst
Phase 1/2Data readout

CR-001

Solid tumor/s

CBIOCrescent Biopharma Inc
Expected catalystMarch 31, 2027Company guidance: Mar 31, 2027

Catalyst overview

Event details

Drug or asset
CR-001
Development stage
Phase 1/2
Event type
Data readout
Indication
Solid tumor/s
Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 1/2 data readout for CR-001 in Solid tumor/s. The expected timing is based on the latest available company guidance and may change.

Development notes

07/30/26:- ASCEND PoC Q1 2027; chemo and sac-TMT combo data Mid-2027; sac-TMT Ph2 underway.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

More from CBIO

Related pipeline programs

Phase 1/2

CR-003 (Topoisomerase Inhibitor ADC)

Solid Tumors

View company pipeline

Company

Crescent Biopharma Inc

CBIO · NasdaqCM
Industry
Biotechnology
Pipeline assets
5
View CBIO research

BioPharma Pro

Track every date change

Watchlists, source history and catalyst alerts will be available with Pro.

Start free

Updated Aug 23, 2026. Dates can change; this is not investment advice.

Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy